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Background: The primary endpoint of head-to-head comparisons of coronary drug-
eluting stents is traditionally assessed after 9-12 months. However, the optimal time
point for assessment of the primary endpoint remains unsettled.
Methods: We randomised 2,332 patients to zotarolimus-eluting Endeavor stent
(E-ZES; n¼1,162) or sirolimus-eluting Cypher stent (C-SES; n¼1,170) implanta-
tion. Endpoints included a composite of cardiac death, myocardial infarction or target
vessel revascularization (MACE) and deﬁnite stent thrombosis. This trial is registered
with ClinicalTrials.gov, number NCT00660478.
Results: At 5-year follow-up, MACE rates were similar in patients treated with E-ZES
and C-SES (197 [17%] vs. 182 [16%]; odds ratio [OR] ¼1.10, 95% conﬁdence
intervals [CI]: 0.88-1.37; p¼0.40). This ﬁnding reﬂected oppositely directed MACE
rates within year 1 (93 [8%] vs. 46 [4%]; OR¼2.13, 95% CI: 1.48-3.07; p<0.001) and
year >1 through 5 (104 [10%] vs. 136 [12%]; OR¼0.78, 95% CI: 0.59-1.02;
p¼0.071). Deﬁnite stent thrombosis was more frequent after E-ZES than C-SES
implantation at 1-year (13 [1.1%] vs. 4 [0.3%]; OR¼3.34, 95% CI: 1.08-10.3;
p¼0.036) while the opposite was found for year >1 through 5 (1 [0.1%] vs. 21
[1.8%]; OR¼0.05, 95% CI: 0.01-0.35; p¼0.003). In the E-ZES and C-SES group,
26 of 88 (30%) and 54 of 70 (77%) of target lesion revascularisations occurred
between 1 and 5 years, respectively.
Conclusions: A traditional 1-year primary endpoint is insufﬁcient to predict 5-year
clinical outcome in patients treated with coronary drug-eluting stent implantation.
Long-term clinical data from routine clinical care populations should be a prerequisite
for unrestricted use of new coronary drug-eluting stents.
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Background: Longterm results with drug eluting stents are important considering late
differences in stent thrombosis, neo-athererosclerosis and catch-up phenomena that
has been observed in several stent studies. Furthermore, little is known of longterm
results with the everolimus-eluting stent, speciﬁcally in comparison with the
paclitaxel-eluting stent.
Methods: 1800 consecutive patients scheduled for PCI have been randomized to
receive a Xience V (EES) or Taxus Liberte (PES) stent. Inclusion criteria were:
patients eligible for PCI and a life expectancy of > 5 years. Major exclusion criteria
were: no expected dual platelet therapy for 12 months, cardiac shock at presentation,
planned major surgery within 1 month. The primary end point is the composite of: all
death, non fatal myocardial infarction (MI) and target vessel revascularization (TVR)
at 12 months. The secondary end points are: A) The combined endpoint of cardiac
death, MI, ischemic driven target lesion revascularization rate at 12 months follow-up.
B) the combined endpoint of all death, MI and TVR rate at 3 and 5 years follow-up.
All patients will be monitored up to 60 months follow-up. Adjudication of events and
core lab analysis of unscheduled angios is done independently by Cardialysis, Rot-
terdam, The Netherlands. A post-hoc SYNTAX score analysis will be done in the
subgroup of multivessel and/or left main treatment.
Results: No differences in patient baseline characteristics and lesion characteristics
were present between both groups. Clinical presentation was similar in both groups
(EES versus PES: Stable angina 40 vs 41%, Unstable angina 12 vs 12%, Non STEMI
22 vs 24%, STEMI 27 vs 23%, respectively). Overall 1.4 lesions per patient have been
treated with an average of 1.6 stents per lesion and an average 2.3 stents per patient,
reﬂecting real world situation with pronounced vessel disease patients. The adjudi-
cation of events between 3 and 5 year follow-up is in progress and will be ready ﬁrst
week September 2013.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: COMPARE is the ﬁrst trial that will show adjudicated longterm data of
EES and in comparison to PES. These 5 year results may have clinical implications,
speciﬁcally for those patients with high SYNTAX scores.
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Background: US guidelines currently recommend 12 months of uninterrupted DAPT
after implantation of DES. Prolonged and more powerful DAPT regimens have
offered beneﬁt by reducing VLST, but at the cost of increased risk of bleeding. There
is an emerging need for new stents that are less dependent on prolonged DAPT. The
BioFreedom stent (BFD) releases Biolimus A9, without using a polymer or binder.
Based on an animal model, 98% of the drug diffuses to the vessel wall within 1 month,
leaving a BMS in place. It is reasonable therefore to consider that the stent offers
a potential safety advantage and a reduced need for prolonged DAPT compared to
a polymer based DES. This First-In-Man trial aims to demonstrate the safety and
effectiveness of theBFDcompared to the Taxus Liberté paclitaxel-eluting stent (PES).
Methods: The BioFreedom FIM is a prospective, multi-center, randomized trial. 182
patients were enrolled and randomized to BFD Standard Dose (SD, 15.6 mg/mm), or
BFD Low Dose (LD, 7.8 mg/mm), or Taxus Liberté DES. The primary endpoint was
in-stent Late Loss (LL) at 12 months. The main secondary endpoints are IVUS
neointimal volume at 4 & 12 months; MACE (death, MI, emergent bypass or
clinically-driven TLR) and ST rates (ARC deﬁned) at 30 days, 4 and 12 months, and
then yearly up to 5 years.
Results: The in-stent LL was non inferior in BFD SD (p non-inferiority ¼ 0.001) and
trended towards superiority with medians of 0.17mm [0.09, 0.39] vs. 0.35mm [0.22,
0.57] compared to PES (p sup¼0.11) at 12 months. At 3 years, the clinical FU was
96%. The BFD SD and PES showed similar rates of MACE (BFD SD 11.9% vs. PES
10.0%) with no deﬁnite/probable ST in any group. Interestingly, at 2 years, there was
a signiﬁcant difference in adherence to DAPT between the groups (BFD SD 5.2% vs.
PES 19% p¼0.025) which disappeared at 3 years.
Conclusions: The safety and efﬁcacy of the polymer free BioFreedom has been
shown out to 3 years. An ongoing trial is studying the possibility of using this stent in
patients with high bleeding risk, unable to tolerate a prolonged course of DAPT. The
BioFreedom FIM 4-year follow-up will be reported for the 1st time during this
presentation.
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Background: A drug-eluting stent consists of 3 components of equal importance:
a metallic platform, a polymer and a drug, all inﬂuencing acute and long term results
both in safety and efﬁcacy. The PLATINUM PLUS trial was designed to compare the
PROMUS Element stent (Boston Scientiﬁc; Natick, MA, US) to the XIENCE
PRIME (Abbot Vascular; Santa Clara, CA, US). These two stents have the same
polymers [poly (n butyl methacrylate) (PBMA) and poly (vinylidene ﬂuoride co
hexaﬂuoropro-pylene) (PVDF-HFP)] and drug (Everolimus) but different platforms
(platinum-chromium for the PROMUS Element, cobalt chromium for the XIENCE
PRIME) and distinct stent designs.
Methods: The trial was designed as a non-inferiority single blind randomized 2:1 trial
(PROMUS Element: P / XIENCE PRIME: X) and recruited from October 2010 to
February 2012 2979 consecutive, all-comer patients in 48 European centers. The
primary endpoint was Target Vessel Failure (TVF: ischemia-driven target vessel
revascularization (TVR), any MI or cardiac death related to the target vessel) at 1 year.acts/ORAL/Bare Metal and Drug-Eluting Stents B5
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tions were 55.9 % stable angina or silent ischemia and 33.1% ACS. Risk factors were
well balanced between the 2 populations: hypertension (68.0% P vs. 68.6% X),
hypercholesterolemia (63.0% P vs. 63.4% X), diabetes (30.1% P vs. 28.1% X),
insulin-treated diabetes (7.8% P vs. 7.1% X), current smoking (22.0% P vs. 20.9% X).
Mean number of stents implanted per patient was 1.7 1.1. Procedural success was
very high in both groups: 97.6% in recipients of PROMUS Element stents and 97.8
% for XIENCE PRIME. At 30 days, clinical events were TVF 1.2% in P vs. 0.8% in
X (p¼0.56) including all death 0.6% in P vs.0.5% in X (p¼0.99), MI 0.7% in P vs.
0.5% in X (p¼0.74) and TVR 0.1 % in P vs. 0.1 in X (p¼0.85), Stent Thrombosis
(deﬁnite and probable) was 0.6% in P vs. 0.2% in X (p¼0.21).
Conclusions: Non inferiority in 30-day outcome was observed between the 2 stents;
the primary endpoint (12-month outcome) will be available for the meeting.
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Background: The incidence of LSD is unknown. The aims of this study were to
estimate the incidence of LSD associated with 4 commonly used DES platforms; to
compare the mechanism of LSD across platforms; to estimate the incidence of major
complications and assess angiographic procedural factors associated with LSD.
Methods: Angiographic and case details for 1,800 PCI cases were examined indi-
vidually by a panel 3 experienced interventional cardiologists. This cohort included
450 consecutive PCI procedures associated with the use of Promus Element, Xience
V, Biomatrix Flex and Resolute Integrity stents respectively. We classiﬁed cases as:
no LSD, LSD, and stent not visible. Cases of LSD were classiﬁed according to
mechanism (guide catheter or secondary device related). Treatment, subsequent
clinical outcome and cases in which re-entry of the stent following LSD was difﬁcult
were recorded.
Results: LSD was detected in a higher proportion with the Promus Element (3.1%)
compared to other platforms (Xience V 0.9%, Biomatrix 0.7%, Resolute 0.7%;
p¼0.002). Guide catheter related LSD occurred equally in all 4 platforms; Promus
Element 1.1%, Xience V 0.9%, Biomatrix 0.7%, Resolute 0.7%; p¼0.85. However, 9/
24 cases were caused by a secondary device, all of which occurred in the Promus
Element stent (p<0.0001). Stent thrombosis occurred in 1 of the 3 cases in which LSD
was not identiﬁed at the time of procedure. Difﬁculty re-entering the deformed stent
was encountered in 6 cases, all of which were in cases of secondary device impact on
Promus Element stents. Univariate predictors of LSD were previous CABG, culprit
vessel, ostial involvement and lesion tortuosity. Multivariate predictors of LSD were
the Promus Element stent, Guideliner use, post-dilation balloons and number of stents
deployed.
Conclusions: LSD is more common than previously reported.LSD in ostial lesions
caused by guide catheter or guide catheter extension occurred equally with all plat-
forms. LSD associated with secondary devices only occurred with the Element stent,
complicating >3% of procedures where it was frequently associated with difﬁculty re-
entering the deformed stent. However, no sequelae were detected when LSD was
recognised and treated.
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Background: Stent fracture (SF) is associated with restenosis and thrombosis. The
contemporary incidence and clinical implications of SF remain uncertain in view of
newer drug-eluting stents (DES). The FDA Manufacturer and User Facility Experi-
ence Database (MAUDE) is an electronic system that aims to capture voluntarily
reported device-related safety issues.
Methods: The MAUDE database was searched from January 2008 through March
2013 for “stent fractures” and “coronary fractures”. Data were extracted with respect
to types of DES, lesion characteristics, presence of overlapping DES, time from index
procedure to SF presentation, clinical presentation of SF, treatments and outcomes of
SF.B6 JACC Vol 62/18/Suppl B j October 27–NovembResults: A total of 126 patients were identiﬁed with coronary SF. The median time
from index procedure, when available, to SF was 17 months [IQR 6-33]. The majority
of patients with SF presented with chest pains and 15.1% had documented acute
coronary syndrome. Most of the SF occurred in lesions with at least moderate
tortuosity (66%) and calciﬁcations (70%). More than half (57.1%) of the reported SF
involved overlapping stents. The observed SF was 41.3% in the LAD, 40.5% in the
RCA, 9% in the LCX and 4% in the vein grafts. There were 29 overlapping stents in
the left anterior descending (LAD) artery (26.9%), 25 in RCA (23.2%) and 4 in LCX
(3.7%), respectively. SF was reported more frequently with Cypher (61.1%), followed
by Xience (16.7%), Promus (9.5%), Endeavor (5.6%), Taxus (4.8%) and BMS (2.4%).
Almost half of reported SF were treated with another DES (54%), 15% had balloon
angioplasty only, 7% underwent CABG, 5% had bare metal stent and another 5% with
medical therapy.
Conclusions: Throughout the DES platform evolution, there are continued SF re-
ported. However, Cypher remained the most commonly reported SF in the MAUDE
database. In accordance with previous reports, Cypher, LAD, RCA, moderate tortu-
osity and calciﬁcations, and overlapping stents were a recurrent observation seen
with SF.
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Background: Stent thrombosis (ST) remains a major concern in patients with acute
coronary syndromes (ACS) treated with drug-eluting stents (DES).
Methods: ADAPT-DES was a multicenter prospective study evaluating outcomes in
8,583 patients treated with DES, aspirin, and clopidogrel, and evaluated with platelet
reactivity testing. The frequency and consequences of 1-year ST (deﬁnite/probable)
were evaluated in the subset of 4,436 patients with ACS (STEMI [n¼813], NSTEMI
[n¼1,250], unstable angina [UA; n¼2,373]).
Results: ST within 1 year occurred in 50 patients (1.1%) and was associated with high
1-year rates of mortality (30.4%) and myocardial infarction (82.6%). ST occurred
more frequently in patients with PAD (2.3% vs 1.0%, p¼0.026), hypertension (1.4%
vs 0.4%, p¼0.008), STEMI vs NSTEMI/UA (1.9% vs 1.0%, p¼0.033), ejection
fraction 40% (2.4% vs 1.0%, p¼0.005), no intravascular ultrasound (IVUS)-
guidance (1.4% vs 0.8%, p¼0.049), stent size 3.0 mm (1.5% vs 0.8%, p¼0.049),
early versus later generation DES (1.5% vs 0.9%, p¼0.043), high platelet reactivity
post clopidogrel (PRU >208) (1.8% vs 0.6%, p<0.001), and premature dual anti-
platelet therapy (DAPT) discontinuation (4.6% vs 1.0%, p¼0.008). Independent
predictors of ST by Cox regression are shown in the Table.er 1, 2013 j TCT Abstracts/ORAL/Bare Metal and Drug-Eluting Stents
